Todas las investigaciones
Activo, no reclutandoFASE2INTERVENCIONISTA

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

This research study is an extension of an earlier study and aims to understand the long-term safety and how a medicine called Votoplam works in people living with Huntington's disease. If you took part in the first study (study PTC518-CNS-002-HD) and finished the treatment period, you might be able to join this one. All participants in this extended study will receive active Votoplam. If you took Votoplam in the first study, you'll continue with the same dose. If you received a dummy medicine (placebo) before, you'll now be given Votoplam at a specific dose. Doctors will monitor how your body responds to the medicine over an additional 54 months (about 4 and a half years). This helps researchers learn more about Votoplam's effects over a longer period.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE2
Patrocinador
Novartis Farmacéutica
Objetivo de inscripción
144
Inicio
25 de ago de 2023
Estimación de finalización
16 Jul 2029

¿De qué trata este estudio?

Huntington's disease is a condition that affects the brain and can lead to changes in movement, thinking, and mental health. There isn't a cure yet, so researchers are always looking for new treatments to help manage the symptoms and slow down the disease's progress.

This study is an important next step in understanding a medicine called Votoplam. If you've already been part of a previous study testing Votoplam (called Study PTC518-CNS-002-HD and identified as NCT05358717), and you completed the treatment part of that study, this new study offers a chance to continue receiving Votoplam. The main aim is to see how safe Votoplam is over a much longer period and how it affects the body and the disease.

By continuing to observe participants for an extra 54 months, researchers hope to gather valuable information about the long-term effects of Votoplam. This kind of extended study is crucial for understanding how a new medicine works over time and helps scientists determine if it could be a helpful treatment for people with Huntington's disease in the future.

Puntos clave

  • This study is an extension of a previous Votoplam trial for Huntington's disease.
  • It aims to understand the long-term safety and effects of Votoplam.
  • Only participants who completed the previous study can join.
  • All participants in this study will receive active Votoplam.
  • The study involves regular check-ups over about 4.5 years.
  • La participación es voluntaria, y puedes retirarte en cualquier momento.

¿Quién puede ser elegible?

To be considered for this study, you must have already completed the full treatment period of the previous Votoplam study (known as Study PTC518-CNS-002-HD). This means you would have finished all the medicines and check-ups required for that earlier study.

If you did not complete the treatment period in the previous study, unfortunately, you would not be able to join this particular extension study. This study is specifically designed for those who have already participated in and completed the initial research.

Please remember that even if you meet these main criteria, there might be other specific reasons why you could or could not join. Your study doctor can give you all the details and help you understand if this study is right for you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Did I complete the treatment part of the previous Votoplam study (PTC518-CNS-002-HD)?
  2. Am I willing to have regular hospital visits and check-ups for about 4.5 years?
  3. Am I comfortable with receiving Votoplam?
  4. Am I at least 25 years old?
  5. Do I have Huntington's Disease?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, you will continue to receive the study medicine, Votoplam, over an extra 54 months. If you received Votoplam in the previous study, you'll continue with the same dose. If you received a dummy medicine (placebo) before, you will now be given Votoplam at a specific dose, which will be decided for you. You won't know which exact dose of Votoplam you are on, and neither will your study team, so that the results can be as fair as possible.

Over these 54 months, you will have regular visits with the study team. During these visits, doctors will perform different assessments to check your health, how you are responding to the medicine, and to see if the medicine is affecting your body in any way. These assessments might include physical exams, blood tests, and other specific tests related to Huntington's disease.

The main aim is to carefully track your progress and look at the long-term safety and effects of Votoplam over approximately four and a half years.

Riesgos y beneficios potenciales

Taking part in this study could offer several potential benefits, such as continued access to Votoplam, a medicine being investigated for Huntington's disease. You will also receive close medical attention and monitoring from a dedicated research team. However, as with any medicine, there are potential risks and side effects that Votoplam might cause, which you will be fully informed about. Some tests you have during the study might also have minor risks, such as discomfort from blood draws. It's important to remember that your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (24)

  • Sitio de Investigación de Novartis
    Código postal verificado
    Clayton, Australia
  • Sitio de Investigación de Novartis
    Código postal verificado
    Westmead, Australia
  • Sitio de Investigación de Novartis
    Código postal verificado
    Innsbruck, Austria
  • Sitio de Investigación de Novartis
    Código postal verificado
    Ottawa, Canada
  • Sitio de Investigación de Novartis
    Código postal verificado
    Angers, France
  • Sitio de Investigación de Novartis
    Código postal verificado
    Marsella, Francia
  • Sitio de Investigación de Novartis
    Código postal verificado
    París, Francia
  • Sitio de Investigación de Novartis
    Código postal verificado
    Berlín, Alemania
  • Sitio de Investigación de Novartis
    Código postal verificado
    Bochum, Alemania
  • Sitio de Investigación de Novartis
    Código postal verificado
    Münster, Germany
  • Sitio de Investigación de Novartis
    Código postal verificado
    Ulm, Germany
  • Sitio de Investigación de Novartis
    Código postal verificado
    Bologna, Italy

Preguntas comunes

¿Cuál es el objetivo principal de este estudio?

The main goal is to understand how safe a medicine called Votoplam is and how it affects people with Huntington's disease over a long period (about 4.5 years).

¿Quién puede unirse a este estudio?

Only people who have already completed the treatment part of a previous Votoplam study (Study PTC518-CNS-002-HD) can join this extension study.

Will I know if I'm getting the actual medicine?

Yes, everyone in this extension study will receive active Votoplam. However, you and your study team usually won't know which specific dose you are receiving to keep the study fair.

How long will I be in this study?

You'll be part of this study for an additional 54 months, which is about four and a half years.

¿Puedo abandonar el estudio si cambio de opinión?

Yes, you are completely free to leave the study at any time, for any reason, and it will not affect your regular medical care.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.